Momenta Pharmaceuticals, Inc. (MNTA)

[Boing x 2]

Wish I knew what the second disease is going to be. Bang that with NO KNOWN TREATMENTS

would be Major as well as the first.


"After discussing plans with the FDA, Momenta said it's going to run proof-of-concept studies testing M281, which lowers immunoglobulin G (IgG) levels, in two different diseases. One trial will be in a disease for which lowering IgG levels has already been shown to help patients, such as myasthenia gravis, idiopathic thrombocytopenic purpura, or pemphigus. And for the second trial, the plan is to test M281 in a disease for which there is no currently approved treatment, potentially allowing a quicker route to approval, albeit with potentially more risk"

Boing X 2